Companies: 10,795·Total market cap: $144.5T
KALA BIO, Inc.

KALA BIO, Inc.

KALANASDAQHealthcare● Active
$2.26
+$0.20(+9.47%)
Market Cap$49452150
P/E Ratio
52W High$1030
52W Low$2.1
SEC Filings

KALA BIO, Inc. (KALA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001479419 · KALA · NASDAQ · as of Jun 8, 2026

Filing snapshot

661
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2017
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001479419 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-15
Fiscal Year End
Apr 15, 2026
Accession No.
0001104659-26-043782
Primary Document
kala-20251231x10k.htm
Source: data.sec.gov · CIK 0001479419 · Accession 0001104659-26-043782

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-15
View
S-3Shelf Registration
S-3
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
10-KAnnual Report
10-K
2026-04-15
View
NT 10-KNT 10-K
NT 10-K
2026-03-31
View
DD
D
2026-03-17
View
8-KCurrent Report
8-K
2026-03-04
View
8-KCurrent Report
8-K
2026-02-20
View
EFFECTEFFECT
EFFECT
2026-02-17
View
424B3424B3
424B3
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
CORRESPCORRESP
CORRESP
2026-02-13
View
UPLOADUPLOAD
UPLOAD
2026-02-13
View
DD
D
2026-02-13
View
Showing 1–15 of 391 filingsForm 4 / 144 hidden· 661 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001479419  |  Exchange: NASDAQ · Healthcare

KALA BIO, Inc. (NASDAQ: KALA) has submitted 661 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001479419, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is KALA BIO, Inc.'s most comprehensive regulatory disclosure. The most recent KALA BIO, Inc. 10-K was filed on 2026-04-15 for fiscal year ending 2026. Historical KALA 10-K annual reports are available from 2009 through 2026.

Investors researching KALA BIO, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

KALA SEC Filings · 8 questions

KALA BIO, Inc. (KALA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 661 filings and access original documents at no cost. KALA BIO, Inc.'s CIK is 0001479419.

KALA SEC filingsKALA BIO, Inc. SEC documentsfind KALA 10-K